ATCC, BioAgilytix Partner
News Oct 19, 2016
ATCC and BioAgilytix have announced a strategic partnership to develop new and custom cell-based assays to accelerate and enhance biopharmaceutical research and development. The partnership combines ATCC’s deep expertise in developing, authenticating, banking, and provisioning cells with BioAgilytix’s world-class capabilities in the development, validation and execution of cell-based assays.
Under the agreement, ATCC will offer tool and reagent development and storage services, including custom-engineered cell lines and primary cells, as a complement to the broad array of assay solutions offered by BioAgilytix. Assays will include those used to establish the potency and stability of therapeutic products and help establish their safety and efficacy profiles.
As part of the relationship, ATCC will take a minority equity stake in BioAgilytix and serve on its commercial advisory board. We believe this partnership will offer significant value to the biopharmaceutical industry,” said Dr. Raymond H. Cypess, ATCC CEO. “The synergies created by combining our recognized expertise in cell line development, storage, management and distribution with the impressive bioanalytical capabilities of BioAgilytix will help advance the progress of innovative therapies for patients in need around the world.”
As a premier CRO specializing in assay development and validation for biotherapeutics, BioAgilytix has established a worldwide reputation for solving complex large molecule challenges, and currently supports 23 of the top 25 global pharmaceutical and biotechnology companies. “To be the best possible partner for our clients, we constantly seek out new opportunities to deliver even greater value and best-in-class services,” said Jim Datin, BioAgilytix CEO.
“ATCC’s 90 years of experience and biorepository operations are a perfect complement to our capabilities. This new partnership will further our ability to deliver industry-leading cell-based assay solutions for drug potency, stability testing and other applications to our clients.”
Chemicals in Lavender and Tea Tree Oil Could be Hormone DisruptorsNews
A new study lends further evidence to a suspected link between abnormal breast growth in young boys--called prepubertal gynecomastia--and regular exposure to lavender or tea tree oil, by finding that key chemicals in these common plant-derived oils act as endocrine-disrupting chemicals.READ MORE
Mending Broken Hearts with Cardiomyocyte MoldsNews
A team of researchers at Michigan Technological University in collaboration with Harvard Medical School, shows how cardiomyocytes grown in a heart-like environment mature more quickly, have improved functionality and are less likely to be rejected by patients’ bodies.READ MORE
Engineered Cartilage Template to Heal Broken BonesNews
A team of UConn Health researchers has designed a novel, hybrid hydrogel system to help address some of the challenges in repairing bone in the event of injury.READ MORE
Comments | 0 ADD COMMENT
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018